Zhitong Finance App News, FuRui Medical Technology (01696.HK) announced that it has been re-authorized to inject botulinum toxin type A (daxibotulinumtoxina-LANM, trademark in China, DAXXIFY® in English, project code RT002, hereinafter referred to as “Daxifil”) has passed the quality standard inspection of the China Food and Drug Administration Research Institute. This product is suitable for temporarily improving moderate to severe interbrow lines in adults due to frowning and/or interbrow muscle activity.

Zhitong Finance App News, FuRui Medical Technology (01696.HK) announced that it has been re-authorized to inject botulinum toxin type A (daxibotulinumtoxina-LANM, trademark in China, DAXXIFY® in English, project code RT002, hereinafter referred to as “Daxifil”) has passed the quality standard inspection of the China Food and Drug Administration Research Institute. This product is suitable for temporarily improving moderate to severe interbrow lines in adults due to frowning and/or interbrow muscle activity.